Cargando…

COVID-19 in multiple sclerosis: The Dutch experience

Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested pos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loonstra, Floor C, Hoitsma, Elske, van Kempen, Zoé LE, Killestein, Joep, Mostert, Jop P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493197/ https://www.ncbi.nlm.nih.gov/pubmed/32662742 http://dx.doi.org/10.1177/1352458520942198

Ejemplares similares

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Tremor in multiple sclerosis
por: Koch, Marcus, et al.
Publicado: (2007)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Mostert, Jop, et al.
Publicado: (2013)

Multiple sclerosis and drug discovery: A work of translation
por: ’t Hart, Bert A., et al.
Publicado: (2021)

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis
por: Lam, KH, et al.
Publicado: (2020)

MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis
por: Koch, Marcus W, et al.
Publicado: (2021)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

gMS-Classifier1 does not predict disability progression in multiple sclerosis
por: van Rossum, Johannis A, et al.
Publicado: (2018)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study
por: van Gorp, Dennis A.M., et al.
Publicado: (2019)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis
por: Hoeijmakers, Aleide, et al.
Publicado: (2023)

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
por: Balk, Lisanne J, et al.
Publicado: (2017)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
por: Sestito, Claudia, et al.
Publicado: (2021)

Gray matter networks and cognitive impairment in multiple sclerosis
por: Rimkus, Carolina M, et al.
Publicado: (2018)

The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth‐year cohort
por: Loonstra, Floor C., et al.
Publicado: (2023)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nf11h70gr2ii5ucfn0stse12vp